Johnson & Johnson

USD, fiscal year ended 2022-01-02

Revenue: Top segments reported by the source sum to more than $78.7B of revenue (a known FMP double-count pattern) - painted without v2 source/hub tags

Operating Expenses: R&D 18% | SG&A 26% of revenue

Revenue

$78.7B

Gross margin

70.3%

Operating margin

26.6%

Net margin

26.5%

Open full screen

Revenue segments

Pharmaceutical: $52.1B66.1%
Medical Devices: $27.1B34.4%
Consumer: $14.6B18.6%

Period history

Revenue, by year

Income statement

Line	FY2021
Revenue	$78,740,000,000
Cost of revenue	$23,402,000,000
Gross profit	$55,338,000,000
Operating expenses	$34,395,000,000
Operating income	$20,943,000,000
Other income/expense, net	-$1,765,000,000
Income before tax	$19,178,000,000
Income tax expense	$1,377,000,000
Net income	$20,878,000,000

Johnson & Johnson

Revenue segments

Period history

Income statement

More in Healthcare

Eli Lilly and Company

UnitedHealth Group Incorporated

Pfizer Inc.